To assess the humoral immune response of two-dose COVID-19 vaccines among CLD patients of different etiologies and identify predictors of "low" versus "high" humoral response
Latest Information Update: 23 Aug 2022
At a glance
- Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 23 Aug 2022 New trial record
- 26 Jun 2022 Results presented at The International Liver Congress 2022